Home Hemodialysis and Patient-Reported Outcomes
Studies of home and frequent hemodialysis suggest improvements in several patient-reported quality-of-life measures, including faster post-dialysis recovery and better physical and mental health domains, compared with conventional in-center hemodialysis.
Background
Patients on conventional thrice-weekly in-center hemodialysis frequently report impaired health-related quality of life, which has been linked to higher morbidity and mortality. Patient-reported outcomes such as quality of life and post-dialysis recovery time are increasingly viewed as essential endpoints when comparing dialysis modalities, motivating evaluation of home-based and more frequent regimens.
Study design
Evidence in this area comes from prospective cohorts and randomized trials of home and frequent hemodialysis using validated instruments such as the SF-36 and Kidney Disease Quality of Life questionnaires. The FREEDOM study followed patients converting to at-home short daily (six times per week) hemodialysis with quality-of-life assessments over 12 months, while the Daily and Nocturnal trials randomized patients to frequent versus conventional schedules and measured changes in quality-of-life domains and recovery time.
Key findings
In the at-home short daily hemodialysis cohort, both physical and mental component summary scores and all eight SF-36 domains improved over 12 months. In the randomized frequent-hemodialysis trials, patients receiving more frequent dialysis reported shorter recovery time after a session, and those treated in-center reported better general health and feeling-thermometer scores compared with conventional thrice-weekly dialysis. Findings across observational comparisons of home versus in-center hemodialysis have been mixed and limited by study quality.
Clinical implications
These data support discussing home and more frequent hemodialysis as options that may improve specific patient-reported quality-of-life measures and reduce post-dialysis recovery burden. Because much of the comparative evidence is observational and heterogeneous, modality choice should be individualized to patient priorities, and larger prospective studies are needed to confirm the magnitude of benefit.
Category
Research
Source
Karger
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.